Business Roundtable
Elusive Cancer Endpoints - How to Survive the Uncertainty
Monday, February 11, 2008
9:30 AM
Astor Salon
There has long been confusion over the ideal design of cancer drug trials and which endpoints are most appropriate to pursue, particularly for cancer vaccines. The issue of whether overall survival or progression-free survival is the better clinical endpoint was most recently highlighted by Dendreon's Provenge. This roundtable brings together a diverse panel of experts who will tackle the most important issues relevant to this tricky topic, provide recommendations on ideal trial design, and discuss how best to work with the FDA.
Moderators
- Greg Frykman, MD; Sr Vice President and Pharmaceutical Analyst, Stanford Group Company
Panelists
- Philip Lavin; Executive Chairman, Averion International Corp.
- David Urdal, Ph.D; Senior Vice President and Chief Scientific Officer, Dendreon
- Kenneth Anderson, MD; Director; Professor; and Chief of Division of Hematological Neoplasia, Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute; Harvard Medical School; and Brigham and Women's Hospital